Safety of Sacubitril-Valsartan, Dapagliflozin, and Eplerenone During Breastfeeding

Medication Safety During Breastfeeding

• The European Society of Cardiology guidelines classify valsartan with unknown transfer to breast milk and list it as FDA Category D during pregnancy due to serious fetal risks including renal dysplasia, oligohydramnios, and growth retardation 1, 2, 3, 4
• Angiotensin II receptor blockers and aldosterone antagonists should be avoided during pregnancy and breastfeeding according to ESC guidelines 4
• The European Society of Cardiology recommends that aldosterone antagonists, such as eplerenone, should be avoided during pregnancy and breastfeeding 4
• In emergency or life-threatening maternal conditions, drugs may need to be used even without complete breastfeeding safety data, as recommended by the European Society of Cardiology 1, 3